The Bronx NY 镰状细胞病临床试验
8项针对 镰状细胞病的研究正在 The Bronx及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
招募中3 期
- Childrens Hospital at Montefiore, The Bronx
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
招募中3 期
- Jacobi Medical Center, The Bronx
- Montefiore Medical Ctr, The Bronx
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
招募中2/3 期
- Jacobi Medical Center, The Bronx
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
招募中观察性研究
- Montefiore Medical Center, The Bronx
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
招募中2 期
- Jacobi Medical Center, The Bronx
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
招募中2 期
- Jacobi Medical Center, The Bronx
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
招募中3 期
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
招募中观察性研究
- Children's Hospital at Montefiore (MRD HCT), The Bronx
- Children's Hospital at Montefiore (NT-DMT), The Bronx
其他城市的 镰状细胞病试验
- Atlanta, GA22 项研究
- Washington, DC20 项研究
- Memphis, TN18 项研究
- Chicago, IL18 项研究
- Philadelphia, PA15 项研究
- Birmingham, AL14 项研究
- New York City, NY13 项研究
- St. Louis, MO12 项研究
- Durham, NC10 项研究
- Cincinnati, OH10 项研究
- Boston, MA10 项研究
- Houston, TX10 项研究
The Bronx的其他研究
- 非小细胞肺癌25 项研究
- 乳腺癌17 项研究
- 急性髓系白血病15 项研究
- 肺癌13 项研究
- 癌症（所有类型）12 项研究
- 心血管疾病12 项研究
- 前列腺癌11 项研究
- 心力衰竭11 项研究
- 头颈鳞状细胞癌9 项研究
- 结直肠癌9 项研究
- 转移性癌症9 项研究
- 哮喘9 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。